Tag - GNCA

Feature

Genocea’s pioneering next generation neoantigen targets T-cell therapy

Genocea Biosciences (NASDAQ:GNCA) is on a mission to make better cancer immunotherapies for patients, beginning with better target discovery.

November 23, 2021

Feature

Genocea Biosciences: for the next generation of immunotherapies, targets matter

Using its unique ATLAS proprietary technology platform, Genocea Biosciences (NASDAQ:GNCA) is developing cancer immunotherapies that direct the body’s own tumor-fighting T-cells to the most therapeutically relevant...

February 18, 2020

Markets

SVB Leerink starts Genocea Biosciences at OP; PT $7

SVB Leerink launched coverage of Genocea Biosciences (NASDAQ:GNCA) with an “outperform” rating and price target of $7. The stock closed at $2.24 on Nov. 14. “Our positive view is based on the promise of Genocea’s ATLAS...

November 15, 2019

Markets

Stifel ups Genocea Biosciences PT to $18 from $5

Stifel hiked its price target for Genocea Biosciences (NASDAQ:GNCA) to $18 from $5 after raising the probability of success to 20% from 15% for Phase 1 efficacy data of the company’s cancer vaccine, GEN-009. The stock...

November 11, 2019

Tag - GNCA

Genocea’s pioneering next generation neoantigen targets T-cell therapy

Genocea Biosciences: for the next generation of immunotherapies, targets matter

SVB Leerink starts Genocea Biosciences at OP; PT $7

Stifel ups Genocea Biosciences PT to $18 from $5

General

More